Methylnaltrexone Bromide Patent Expiration
Methylnaltrexone Bromide is Used for managing opioid-induced constipation. It was first introduced by Salix Pharmaceuticals Inc
Methylnaltrexone Bromide Patents
Given below is the list of patents protecting Methylnaltrexone Bromide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Relistor | US10307417 | Oral formulations and lipophilic salts of methylnaltrexone | Mar 10, 2031 | Salix |
| Relistor | US10376505 | Oral formulations and lipophilic salts of methylnaltrexone | Mar 10, 2031 | Salix |
| Relistor | US8524276 | Oral formulations and lipophilic salts of methylnaltrexone | Mar 10, 2031 | Salix |
| Relistor | US8956651 | Oral formulations and lipophilic salts of methylnal trexone | Mar 10, 2031 | Salix |
| Relistor | US9314461 | Oral formulations and lipophilic salts of methylnaltrexone | Mar 10, 2031 | Salix |
| Relistor | US8247425 | Peripheral opioid receptor antagonists and uses thereof | Dec 31, 2030 | Salix Pharms |
| Relistor | US8420663 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix |
| Relistor | US8420663 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix Pharms |
| Relistor | US8822490 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix Pharms |
| Relistor | US9180125 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix |
| Relistor | US9180125 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix Pharms |
| Relistor | US9492445 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix |
| Relistor | US9492445 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix Pharms |
| Relistor | US9724343 | Peripheral opioid receptor antagonists and uses thereof | Sep 30, 2029 | Salix |
| Relistor | US10376584 | Stable pharmaceutical formulations of methylnaltrexone |
Apr 08, 2024
(Expired) | Salix Pharms |
| Relistor | US8552025 | Stable methylnaltrexone preparation |
Apr 08, 2024
(Expired) | Salix Pharms |
| Relistor | US9669096 | Stable pharmaceutical formulations of methylnaltrexone |
Apr 08, 2024
(Expired) | Salix Pharms |
| Relistor | US6559158 | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov 03, 2017
(Expired) | Salix |
| Relistor | US6559158 | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
Nov 03, 2017
(Expired) | Salix Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Methylnaltrexone Bromide's patents.
Latest Legal Activities on Methylnaltrexone Bromide's Patents
Given below is the list recent legal activities going on the following patents of Methylnaltrexone Bromide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8247425 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2023 | US9314461 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2023 | US9180125 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jan, 2023 | US10376505 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jan, 2023 | US10376584 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Nov, 2022 | US10307417 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jul, 2022 | US8956651 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Feb, 2022 | US8822490 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Mar, 2021 | US8552025(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Feb, 2021 | US8524276 |
Methylnaltrexone Bromide's Family Patents
Explore Our Curated Drug Screens
Methylnaltrexone Bromide Generic API Manufacturers
Several generic applications have been filed for Methylnaltrexone Bromide.
Given below is the list of companies who have filed for Methylnaltrexone Bromide generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS LLC
Actavis Llc has filed for 2 different strengths of generic version for Methylnaltrexone Bromide. Given below are the details of the strengths of this generic introduced by Actavis Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 8MG/0.4ML (8MG/0.4ML) | solution | Prescription | SUBCUTANEOUS | AP | Aug 26, 2024 |
| 12MG/0.6ML (12MG/0.6ML) | solution | Prescription | SUBCUTANEOUS | AP | Aug 26, 2024 |
Manufacturing Plant Locations New
Actavis Llc's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Actavis Llc as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||